Although sclerostin is reported to be expressed in the aorta,51, 52, 53 neither Sost KO mice in this study or others nor human patients with sclerosteosis or van Buchem's disease due to mutations in the SOST gene exhibit any greater risk of cardiovascular complications.54, 55, 56, 57 Furthermore, a case study by van Lierop et al58 reported that GC treatment does not lead to adverse cardiovascular effects in a van Buchem high bone mass patient with mutation in the SOST gene. The gene discussed is SOST; the disease is sclerosteosis.